Aktienanalyse zu Artelo Biosciences, Inc (ARTL)ARTLArtelo Biosciences, Inc

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Artelo Biosciences Inc is not a good buy right now due to its current price of $1.96, which is down 94.29% year-to-date, and an RSI of 19.984 indicating it is oversold. The company is experiencing significant losses, with a net income of -$2,958,000 in Q1 2026, and a forward P/E ratio of 0, suggesting no earnings growth is expected in the near term. The main risk is the continued decline in stock value, as evidenced by a 96.57% drop over the past year.